Results 61 to 70 of about 71,266 (230)

Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril

open access: yes, 1995
The pathogenesis of renal scarring in chronic cyclosporin nephropathy is unknown. In this study, we evaluated the effects of renin-angiotensin system blockade by enalapril and losartan in a salt-dependent model of cyclosporin-associated chronic ...
T. F. Andoh   +7 more
core   +1 more source

Lethal and Sublethal Toxicity Assessment of Cyclosporin C (a Fungal Toxin) against Plutella xylostella (L.)

open access: yesToxins, 2022
Secondary metabolites/toxins produced by Purpeocillium lilacinum (Hypocreales; Phiocordycipitaceae), a well-known insect pathogen, can be used for the management of different insect pests.
Jianhui Wu   +3 more
doaj   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

The effect of cyclosporin and lipopolysaccharide on fibroblasts: Implications for cyclosporin-induced gingival overgrowth

open access: yes, 1992
Drug-induced gingival overgrowth is an adverse side effect associated principally with 3 different types of drugs; specifically the antiepileptic phenytoin, the calcium channel antagonist nifedipine, and the immunosuppressant cyclosporin.
Seymour G.J., Barber M.T., Savage N.W.
core   +1 more source

Effectiveness and Safety of Vunakizumab Over 12 Weeks in Chinese Patients With Plaque Psoriasis: A Prospective, Real‐World Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu   +4 more
wiley   +1 more source

Papular dermatitis: response to cyclosporin

open access: yes, 2000
BACKGROUND/AIM: Papular dermatitis is a persistent pruritic papular dermatitis, often refractory to treatment. The objective was to examine the effectiveness of cyclosporin for the treatment of this condition.
Hendi, A   +7 more
core   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija   +6 more
wiley   +1 more source

Kaposi's sarcoma in kidney transplant recipients treated with cyclosporin

open access: yes, 1988
We report the clinical and histological features and the course of Kaposi's sarcoma in three transplant patients treated with cyclosporin. Four months after cyclosporin treatment was stopped the lesions in all three patients had completely ...
P. L. Bencini   +3 more
core   +1 more source

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients.
Andrea Henden   +13 more
wiley   +1 more source

A cyclosporin A-sensitive mitochondrial pore [PDF]

open access: yes, 1993
Cyclosporin-A is a potent immunosuppressant used to prevent graft rejection. Work in this laboratory has suggested a novel action of cyclosporin, namely protection against the cell injury caused by energy deprivation e.g.
McGuinness, Orla Mary
core   +1 more source

Home - About - Disclaimer - Privacy